Who
Julie Burgess
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Design Therapeutics.
In numbers
- Trades disclosed
- 7
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2021
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
| 2 Jan 2024filed 5 Jan 2024 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Feb 2023filed 3 Feb 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Feb 2022filed 2 Feb 2022 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Oct 2021filed 4 Oct 2021 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —135,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.